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A 19-year-old boy presented to ambulatory clinic with shortness of breath after walking two blocks. He
denied any cough, orthopnea, chest pain or hemoptysis. Ten months prior to admission he was admitted
to the medical intensive care unit with respiratory failure and was diagnosed with Goodpasture
syndrome. He was treated with cyclophosphamide and steroids. He was discharged home after recov-
ering. Patient subsequently developed dyspnea on minimal exertion. Spirometry showed severe
obstructive lung disease and HRCT of chest showed diffuse micronodular disease with patchy ground-
glass opacities, mild bronchiectasis and bronchiolectasis. Serologies for goodpasture syndrome were
normal. A diagnosis of post-Goodpasture syndrome constrictive bronchiolitis was made. Due to severity
of symptoms he was treated with azithromycin. His FEV1 doubled in 3 months and in addition to
signiﬁcant clinical improvement the HRCT ﬁndings also improved. This is the ﬁrst described case of
constrictive bronciolitis developing as an aftermath of Goodpasture syndrome.
Published by Elsevier Ltd.1. Case report
A 19-year-old man presented to ambulatory clinic with an eight
month history of shortness of breath progressing to the point that
he could walk only two blocks. He denied any cough, orthopnea,
chest pain or hemoptysis. Approximately 10 months prior to this
presentation he was admitted to the medical intensive care unit
due to progressively worsening shortness of breath, non-produc-
tive cough, chills and respiratory failure. He was diagnosed with
Goodpasture syndrome after a surgical lung biopsy revealed
changes compatible with the diagnosis and positive anti-glomer-
ular basement membrane antibody (Anti-GBM) serology. He was
treatedwith cyclophosphamide and steroids. He recovered andwas
discharged from the hospital on oral cyclophosphamide 150 mg
daily and prednisone 10 mg daily. His anti-GBM serology had
stayed negative since discharge. He admitted to smoking marijuana
occasionally and smoking half a pack per day of cigarettes prior tory, Critical Care and Sleep
55 West 8th Street, Jackson-
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ido), james.cury@jax.uﬂ.eduhospitalization but denied using it currently. A review of other
systems was negative.
Vital signs were normal except mild resting tachycardia with
pulse 103 per minute. His physical exam was normal with the
exception of diminished breath sounds bilaterally with prolonged
expiration.
Laboratory datawas signiﬁcant for an anti-GBM titer of less than
20 units (0–20), serum bicarbonate 30 meq/L (21–29), WBC count
8500/mL. Echocardiogram revealed mild global left ventricular
dysfunction with ejection fraction 50–55%. Complete pulmonary
function testing showed severe airﬂowobstruction FEV10.98 (26%),
severely reduced DLCO (19%) and no response to bronchodilator.
During a six minute walk test he walked a total of 200 m and
required3 l of oxygen tomaintainhis oxygen saturation at 91% at the
end of the test. Postero-anterior and lateral chest radiography stable
scarring from his previous lung biopsy (Fig. 1). Further evaluation
with a chest CT scan showed diffuse micronodulr lung disease with
evidence of bronchiectasis and bronchiolectasis (Fig. 2 A).
Patient refused to undergo bronchoscopy or to have a surgical
lung biopsy done. A clinical diagnosis of post-Goodpasture’s
syndrome constrictive bronchiolitis was made and he was treated
with azithromycin 250 mg orally three times weekly. His cyclo-
phosphamide was stopped but prednisone was continued. He
responded well to treatment. After 3 months of therapy his FEV1
improved to 1.52 (51%) and DLCO improved to 53%. His 6 min walk
distance increased to 384 m and oxygen saturation improved to
90% at the end of test on room air. A repeat chest CT chest was
performed (Fig. 2B).
Fig. 1. Postero-anterior and lateral chest radiograph showing scarring in left lung at the site of surgical lung biopsy.
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Bronchiolitis is the most common disease affecting the small
airways and can occur due to a variety of infectious or inﬂammatory
causes. Although clinical, physiological, radiological and histolog-
ical ﬁndings are helpful in differentiating the bronchiolar disorders,
no single classiﬁcation scheme for this group of disorders has been
widely accepted.1,2 The classiﬁcation scheme (Table 1) proposed by
Ryu et al. divides bronchiolar disorders into three majorFig. 2. A. Computed tomography of chest atcategories.3 Based on clinical, physiological and radiological ﬁnd-
ings our patient likely had constrictive bronchiolitis. A variety of
conditions (Table 2) have been associated with constrictive bron-
chiolitis.3 Although constrictive bronchiolitis has been associated
with a host of exposures, autoimmune, malignant and infectious
etiologies, to date there have been no reports of it developing after
Goodpasture syndrome.
Constrictive bronchiolitis clinically presents with sub-acute
onset of cough, progressive decline in exercise tolerance andbaseline. B. After 3 months of therapy.
Table 1
Classiﬁcation of bronchiolar disorders.
Primary bronchiolar disorders
Constrictive bronchiolitis (obliterative bronchiolitis, bronchiolitis
obliterans)
Acute bronchiolitis
Diffuse panbronchioliti
Respiratory bronchiolitis (smoker’s bronchiolitis)
Mineral dust airway disease
Follicular bronchiolitis
Other primary bronchiolar disorders (e.g., diffuse aspiration bronchiolitis,
lymphocytic bronchiolitis)
Interstitial lung diseases with a prominent bronchiolar involvement
Hypersensitivity pneumonitis
Respiratory bronchiolitis–associated interstitial lung disease/desquamative
interstitial pneumonia
Cryptogenic organizing pneumonia (idiopathic bronchiolitis obliterans
organizing pneumonia or proliferative bronchiolitis)
Other interstitial lung diseases (pulmonary Langerhans’ cell histiocytosis,
sarcoidosis,
bronchiolocentric interstitial pneumonia)
Bronchiolar involvement in large airway diseases
Chronic bronchitis
Bronchiectasis
Asthma
Table 2
Causes and underlying disorders associated with constrictive bronchiolitis.
1: Cryptogenic constrictive bronchiolitis
2: Postinfectious including most commonly viruses (adenovirus, respiratory
syncytial virus, inﬂuenza, parainﬂuenza, etc.) and mycoplasma
3: Connective tissue diseases (rheumatoid arthritis and eosinophilic fasciitis)
4: Inhalational injury (nitrogen dioxide, sulfur dioxide, ammonia, chlorine,
phosgene, hot gases, ﬂy ash)
5: Ingested toxins (e.g., Sauropus androgynus)
6: Allograft recipients (heart–lung or lung transplant, bone marrow transplant)
7: Drugs (penicillamine, lomustine, cocaine, gold, penicillamine, etc.)
8: Other associations: inﬂammatory bowel diseases, neuroendocrine cell
hyperplasia and multiple carcinoid tumorlets
9: Paraneoplastic pemphigus
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typically reveals evidence of airway obstruction with air trapping
and reduction in diffusion capacity. High resolution CT scan (HRCT)
ﬁndings include mosaic areas of decreased attenuation, peripheral
bronchiectasis, bronchiolectasis, and nodular or reticulonodular
opacities.4 Given the range of etiologies that can result in
constrictive bronchiolitis it is very likely that there is a host of
pathogenetic mechanisms that play a role, but all leading to
a similar histopathological pattern. The characteristic ﬁnding on
pathology is of peribronchiolar ﬁbrosis ranging from very subtle
abnormalities to complete luminal obliteration. The inﬂammatory
ﬁbrosis surrounds the lumen of the bronchiole rather than ﬁlling
it.2,3 Transbronchial lung biopsy is relatively insensitive because of
patchy and often subtle areas of peribronchiolar ﬁbrosis and usually
a surgical lung biopsy is needed to conﬁrm the diagnosis. The
classic features seen on HRCT in combination with pulmonary
function testing and appropriate clinical setting may sufﬁce to
establish the diagnosis of constrictive bronchiolitis.
Azithromycin has been successfully used as maintenance
therapy in lung transplant recipients for treatment of bronchiolitis
obliterans syndrome.5–7 Beneﬁcial effects include not only pre-
venting a decline in lung function but also to improving lung
function in BOS. There is a progressive decline in FEV1 in patients
with constrictive bronchiolitis as the result of the inﬂammatoryresponse of the epithelium and its excessive repair. Azithromycin
has been reported to have anti-inﬂammatory effects by reducing
interleukin 8 and airway neutrophilia in patients with BOS.6 HRCT
may also be very helpful in following the course of constrictive
bronchiolitis to document reduction in the size of nodules, bron-
chiolectasis and improvement of mosaic attenuation on macrolide
treatment.
Our patient had the clinical features, radiological ﬁndings and
pulmonary function tests that were characteristic of constrictive
bronchiolitis. The fact that a signiﬁcant improvement in all of these
aspects occurred after 3 months of empiric therapy with low dose
Azithromycin further strengthens our diagnosis.
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